Information Provided By: 
Fly News Breaks for October 20, 2017
STAA
Oct 20, 2017 | 09:01 EDT
Benchmark analyst Raymond Myers called Q4 "a pivotal time" for STAAR Surgical and he raised his price target on the stock to $15 from $13 on the anticipation of FDA progress this quarter. Myers, who thinks the long-term FDA remediation effort can soon transition to new product applications, believes Toric approval is likely in 2018, he tells investors. He keeps a Buy rating on STAAR shares.
News For STAA From the Last 2 Days
There are no results for your query STAA
